All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
7th European CAR T-cell Meeting congress coverage
Bookmark this article
Catch up with our live social media coverage of lymphoma and chronic lymphocytic leukemia from the 7th European CAR T-cell Meeting
CONGRESS | #CART25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) February 6, 2025
Pere Barba @UABBarcelona presented results from a phase II study of rapcabtagene autoleucel in patients with R/R DLBCL.
N=63, ORR was 88.3%, CRR was 65%. Median DoR was 15.2 months, median PFS was 11.9 months, 12-months OS was 83%. The safety… pic.twitter.com/PbQnY1Vy5L
CONGRESS | #CART25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) February 6, 2025
Tanya Siddiqi @cityofhope shares insights of using CAR T-cell therapy for patients with #CLL using encouraging data from the phase I/II TRANSCEND CLL 004 trial of lisocabtagene maraleucel combined with ibrutinib in patients with R/R CLL/SLL.… pic.twitter.com/8LsrQhO72h
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
82 votes - 79 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox